FeesSafety
Pluang+

ProMIS licenses TXP1 tech to boost brain delivery of Alzheimer's antibody PMN310 and expand pipeline.

Company Fundamentals
17 Nov 2026, 09:30 WIB
GlobeNewsWire
View Source
Bullish
ProMIS licenses TXP1 tech to boost brain delivery of Alzheimer's antibody PMN310 and expand pipeline.

ProMIS Neurosciences has licensed TXP1, a brain-selective shuttling technology from Ossianix, to enhance delivery of its Alzheimer's antibody PMN310 by over 65-fold in preclinical studies. This license supports lifecycle management of PMN310 and offers options to extend TXP1 use to Parkinson's and ALS programs. TXP1's small VNAR antibody scaffold shows promising brain targeting with minimal side effects, potentially enabling more convenient dosing and lower costs. ProMIS plans to advance PMN310 as both intravenous and subcutaneous treatments, aiming for improved patient outcomes and pipeline expansion.

ProMIS Neurosciences' recent licensing of TXP1 brain-selective shuttling technology comes amid a Health sector where 33 of 150 US stocks rose and 116 fell on Pluang as of Nov 17, 2026, 13:12 WIB. Notable movers include FLNA (Cassava Sciences Inc) with a 10.56% gain and a typical hold time of 39 days, and SYRE (Spyre Therapeutics Inc.) down 12.52% with a 6-day hold time. DNA (Ginkgo Bioworks Holdings Inc) also declined by 11.97% with a 10-day typical hold time.

More News

Commit Biologics raises $60M seed round to advance novel immune therapy for cancer and autoimmune diseases

Commit Biologics raises $60M seed round to advance novel immune therapy for cancer and autoimmune diseases

Commit Biologics secured $60 million in seed funding led by Ackermans & van Haaren with participation from AbbVie Ventures, M Ventures, and others. The funds will support clinical development of COM002, a first-in-class immune engager targeting cance...

Company Fundamentals
Bullish
1 hour ago
Dassault Systèmes targets double-digit revenue and EPS growth by 2029 with AI-driven industrial solutions.

Dassault Systèmes targets double-digit revenue and EPS growth by 2029 with AI-driven industrial solutions.

Dassault Systèmes announced at its 2026 Capital Markets Day a new growth cycle aiming for double-digit revenue and EPS growth by 2029, targeting over €8 billion in revenue and €1.80 in non-IFRS diluted EPS. The company highlights its transition to su...

Market News
Bullish
1 hour ago
Dassault Systèmes targets double-digit revenue and EPS growth by 2029, driven by AI and subscription model.

Dassault Systèmes targets double-digit revenue and EPS growth by 2029, driven by AI and subscription model.

Dassault Systèmes announced a new growth cycle aiming for double-digit increases in revenue and diluted EPS by 2029, with revenue expected to exceed €8 billion and EPS €1.80. This growth is supported by a strong subscription model, accelerating adopt...

Company Fundamentals
Bullish
1 hour ago
Fundstrat's US Small- & Mid-Cap ETF underperforms amid tech rotation and election impact.

Fundstrat's US Small- & Mid-Cap ETF underperforms amid tech rotation and election impact.

The Fundstrat Granny Shots US Small- & Mid-Cap ETF (GRNJ) has recently underperformed due to a rotation away from tech stocks and the effects of election results. Despite this, GRNJ's investment approach aligns with Fundstrat's successful large-cap E...

Neutral
5 hours ago
Plains All American Pipeline offers 7% yield amid Permian growth but faces leverage and oil price risks

Plains All American Pipeline offers 7% yield amid Permian growth but faces leverage and oil price risks

Plains All American Pipeline (PAA) is now focused on crude oil midstream operations with significant exposure to the Permian Basin after recent asset sales and acquisitions. The company offers a 7% dividend yield supported by strong distribution cove...

Analyst Insights
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App